| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today announces a late-breaking abstract has been accepted and selected as a Proffered Paper oral presentation at the 2025 European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany from October 17-21, 2025.
The oral presentation will highlight the results from the randomized Phase 3 trial assessing the efficacy and safety of IO102-IO103 (IDO/PD-L1 vaccine) in combination with pembrolizumab vs pembrolizumab monotherapy in 1L advanced melanoma. In addition, final data from the Phase 2 basket trial with updated efficacy and safety data, median progression-free survival (PFS), landmark PFS and overall survival data, as well as biomarker and translational data for 1L treatment in non-small cell lung cancer (NSCLC) and squamous cell carcinoma of head and neck (SCCHN), will be presented in a poster session. Details of the presentations are as follows:
| Title: | IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma: Primary Phase 3 results (IOB-013/KN-D18) |
| Speaker: | Jessica Hassel, MD, Professor at the Department of Dermatology and National Center for Tumor Diseases at the University Hospital Heidelberg Germany |
| Category: | Proffered Paper Session: Melanoma and other skin tumours |
| Date & Time: | Monday, October 20, 2025; 8:30 – 10:00 CEST |
| Lecture time: | 9:50 – 10:00 CEST |
Late-breaking abstracts at ESMO are generally reserved for high-quality, new research findings from randomized Phase 2 or Phase 3 trials with implications for clinical practice or understanding of disease processes. Proffered papers are oral presentations of original data of superior quality, followed by expert discussion and perspectives.
| Title: | IO102-IO103 cancer vaccine plus pembrolizumab for first line (1L) treatment of advanced solid tumors: Final results of a Phase 2 basket trial |
| Presenter: | Jonathan W. Riess, MD, MS, UC Davis Comprehensive Cancer Center |
| Category: | Investigational immunotherapy |
| Presentation #: | 1557P |
| Date & Time: | Sunday, October 19, 2025; 12:00 – 12:45 CEST |
The poster may be found on the "Posters & Publications" page of the IO Biotech website at the start of the meeting.
Posted In: IOBT
